Lopatin Iu M, Dronova E P
Kardiologiia. 2009;49(2):15-21.
The aim of this study was to evaluate clinical and pharmacoeconomic effects of long-term use of trimetazidine MR in patients with ischemic heart disease (IHD) undergoing coronary artery bypass grafting (CABG). Patients with IHD (n=306) were included in open, prospective, randomized clinical trial. One group (group 1, n=153) was pretreated with trimetazidine MR two weeks prior to CABG and continued to take trimetazidine MR for 3 years after the procedure. The other group without of trimetazidine MR (group 2, n=153) was the group of comparison. All patients received conventional therapy of IHD. Six hours after CABG serum creatinine kinase and creatinine-kinase MB were significantly lower in group 1 than in group 2. Rate of ischemic events was also lower in patients treated with trimetazidine MR. Long-term use of trimetazidine MR was characterized by improvement of left ventricular systolic function and exercise tolerance and associated with lower expenses for treatment. We concluded that trimetazidine MR appeared to reduce myocardial reperfusion injury after CABG in patients with IHD.
本研究旨在评估长期使用缓释曲美他嗪对接受冠状动脉旁路移植术（CABG）的缺血性心脏病（IHD）患者的临床和药物经济学效果。将306例IHD患者纳入开放性、前瞻性、随机临床试验。一组（第1组，n = 153）在CABG术前两周接受缓释曲美他嗪预处理，并在术后继续服用3年。另一组未使用缓释曲美他嗪（第2组，n = 153）作为对照组。所有患者均接受IHD的常规治疗。CABG术后6小时，第1组血清肌酐激酶和肌酸激酶同工酶水平显著低于第2组。使用缓释曲美他嗪治疗的患者缺血事件发生率也较低。长期使用缓释曲美他嗪的特点是左心室收缩功能和运动耐量得到改善，且治疗费用较低。我们得出结论，缓释曲美他嗪似乎可减轻IHD患者CABG术后的心肌再灌注损伤。
